Introduction {#s1}
============

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a newly recognized acute form of encephalitis caused by anti-neuronal autoantibody; anti-NMDAR encephalitis is potentially lethal and mainly affects children and young women ([@B1], [@B2]). Anti-NMDAR encephalitis can develop with multistage presentation and a wide spectrum of neuropsychiatric features. The early-phase involves nonspecific prodromes such as fatigue, fever and headache. In late-phase, impaired consciousness, cognitive deficits, seizures, profound psychiatric symptoms, dysautonomia, and central hypoventilation often emerge, necessitating intensive care treatment ([@B3]--[@B5]). One of the challenges for management of anti-NMDAR encephalitis is the lack of available biomarkers for monitoring and predicting prognosis. The hallmarks of neuroinflammation in anti-NMDAR encephalitis should be thoroughly investigated to improve treatment and patient outcomes.

Anti-NMDAR encephalitis is caused by autoantibodies which primarily target the NR1 subunit of the NMDAR. Transformation of B and T lymphocytes is thought to be involved in the inflammatory injury that occurs with anti-NMDAR encephalitis ([@B6]). Gliosis, microglia proliferation and IgG deposition are suggested to be the most prominent histopathological features of the disease ([@B7]). YKL-40 (chitinase 3-like 1 or HCgp39) is a secreted glycoprotein belonging to the glycosyl hydrolase 18 family. In the central nervous system (CNS), YKL-40 is mostly expressed by microglia, especially when responding to acute and chronic inflammation ([@B8], [@B9]). An increase of YKL-40 in the brain and/or cerebrospinal fluid (CSF) is associated with a variety of immune and inflammatory diseases, particularly neurological and neurodegenerative diseases with an inflammatory component, such as multiple sclerosis (MS), Alzheimer\'s disease (AD), and stroke ([@B10]--[@B12]). However, little is known about what inflammatory mediators regulate YKL-40 or the underlying molecular mechanisms behind this regulation. In the present study, we aimed to investigate the YKL-40 profile in patients with anti-NMDAR encephalitis and to evaluate possible associations between YKL-40 and modified Rankin Scale (mRS) scores, as well as the expression of inflammatory cytokines.

Materials and method {#s2}
====================

Patients and controls
---------------------

This study enrolled 33 patients with anti-NMDAR encephalitis, 13 patients with viral meningitis (VM) and 20 controls. The diagnosis of anti-NMDAR encephalitis was confirmed using criteria which included the presence of clinical manifestations and detection of anti-NMDAR antibodies in the CSF using a cell-based assay ([@B2], [@B13]). Patients with non-inflammatory neurological disease were used as controls, including 15 cases of mild white matter degeneration and 6 cases of movement disorders. The etiologies of viral meningoencephalitis included 7 cases of herpesvirus and 6 cases of varicella zoster virus (Table [1](#T1){ref-type="table"}). Within 3 days of admission, all patients were subjected to a lumbar puncture procedure for CSF analysis, patients with anti-NMDAR encephalitis received a follow-up lumbar puncture for CSF re-evaluation 3 months after discharge. All patients with anti-NMDAR encephalitis received tumor screening at least once during hospitalization using computed tomography, magnetic resonance imaging or B-scan. The neurological status of patients was assessed using the mRS ([@B14]) at both onset and at the 3 month follow-up after discharge. Treatments for anti-NMDAR encephalitis included first-line immunotherapy, second-line immunotherapy and tumor removal.

###### 

The demographic data of patients with anti-NMDAR encephalitis (*n* = 33), viral meningitis (*n* = 13) and controls (*n* = 20).

  **Characteristic**                                      **Anti-NMDAR encephalitis**   **Viral meningitis**   **Controls**
  ------------------------------------------------------- ----------------------------- ---------------------- -------------------
  Gender (female/male)                                    19/14                         5/8                    13/8
  Age (years, mean ± SD)                                  34.8 ± 17.5                   35.7 ± 15.7            34.81 ± 13.32
  Symptom onset (n, %)                                                                                         
        Prodromal symptoms                                16 (48.5)                     0                      --
        Psychiatric symptoms                              32 (97.0)                     2                      --
        Memory deficits                                   6 (18.2)                      3                      --
        Speech disturbances                               2 (6.0)                       0                      --
        Seizures                                          22 (66.7)                     1                      --
        Movement disorders                                7 (21.2)                      0                      --
        Loss of consciousness                             21 (63.6)                     0                      --
        Central hypoventilation                           7 (21.2)                      0                      --
        Ovarian teratoma                                  2 (6.1)                       0                      --
        mRS                                               4.2 ± 0.9                     --                     --
        3 month mRS                                       2.7 ± 1.2                     --                     --
        CSF anti-NMDAR antibody                           33                            0                      0
  Treatment (n, %)                                                                                             
        First line treatment                              22 (66.7)                     --                     --
        Second-line treatment                             11 (33.3)                     --                     --
  Onset                                                                                                        
        YKL-40 (pg/ml)[^\*^](#TN1){ref-type="table-fn"}   128.3 (97.0--171.4)           94.7 (77.1--113.6)     82.4 (67.4--93.4)
        TNF-α (pg/ml)                                     6.0 (4.3--11.3)               5.27 (3.4--11.3)       1.1 (0.2--2.2)
        IL-6 (pg/ml)                                      7.3 (3.9--13.4)               4.6 (3.4--6.7)         3.1 (2.7--4.1)
        IL−10 (pg/ml                                      4.9 (3.6--5.8)                3.21 (2.0--5.7)        0.9 (0--1.1)
  3 month follow-up                                                                                            
        YKL-40 (pg/ml)                                    121.1 (106.4--173.0)          --                     --
        TNF--α (pg/ml)                                    3.5 (2.31--8.3)               --                     --
        IL-6 (pg/ml)                                      7.3 (5.7--8.2)                --                     --
        IL-10 (pg/ml)                                     2.7 (1.3--4.8)                --                     --

*Data were presented as the median (interquartile range)*.

Enzyme-linked immunosorbent assay (ELISA)
-----------------------------------------

CSF samples were centrifuged immediately after collection to isolate cells and larger particles, then stored at −80°C for future testing. Commercially available sandwich ELISA kits were used to detect CSF concentrations of YKL-40 (Quantikine ELISA, R&D Systems), TNF-α (Cusabio, Wuhan, China), IL-6, and IL-10 (Bender MedSystems GmbH, Vienna, Austria). ELISA assays were performed according to the manufacturers\' instructions for each kit.

Follow-up evaluation
--------------------

A total of 15 patients with anti-NMDAR encephalitis received a follow-up evaluation 3 months after discharge. The follow-up evaluation included mRS assessment and CSF tests.

Statistical analysis
--------------------

All statistical analyses were performed using SPSS 20.0 (IBM Corp, Armonk, NY, USA). Because the data were non-parametrically distributed, statistical analysis to compare levels of YKL-40 and cytokines between anti-NMDAR encephalitis and control groups was conducted with the Kruskal-Wallis *H*-test. Spearman test was performed to evaluate correlations between CSF cytokines and mRS scores. A receiver Operator Characteristic (ROC) curve was used to evaluate the diagnostic value of CSF YKL-40 between anti-NMDAR encephalitis and controls. A value of *p* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Increased CSF levels of YKL-40 and cytokines in patients with anti-NMDAR encephalitis
-------------------------------------------------------------------------------------

To investigate the role of YKL-40 in anti-NMDAR encephalitis, we measured the CSF level of YKL-40 in patients with anti-NMDAR encephalitis (*n* = 33), VM (*n* = 13), and controls (*n* = 20) using an ELISA assay. As shown in Figure [1A](#F1){ref-type="fig"}, the levels of YKL-40 in the CSF of anti-NMDAR encephalitis patients at the onset of disease (median 128.3 pg/mL; interquartile range 97--171.4 pg/mL) were significantly higher than those of VM patients (94.7 pg/mL; 77.1--113.6 pg/mL) and controls (82.4 pg/mL; 67.35--93.35 pg/mL) (*p* = 0.017, *p* \< 0.001, respectively).

![Levels of YKL-40 and cytokines in cerebrospinal fluid (CSF) and association with modified Rankin Scale (mRS). YKL-40 **(A)** and cytokines **(B)** levels in the CSF of patients with anti-NMDAR encephalitis, viral meningitis (VM) and controls; **(C)** Receiver operating characteristic curves for YKL-40 to discriminate anti-NMDAR encephalitis patients from control patients. **(D)** Correlation between YKL-40 levels and IL-6 in anti-NMDAR encephalitis subjects. **(E)** Correlation between decrease of YKL-40 levels and decrease of IL-6 levels in anti-NMDAR encephalitis patients in 3 month follow-up. **(F)** Correlation between decrease of YKL-40 levels and decrease of mRS scores in anti-NMDAR encephalitis patients in 3 month follow-up. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.](fneur-09-00727-g0001){#F1}

CSF levels of the pro-inflammatory cytokines TNF-α and IL-6 were significantly higher in anti-NMDAR encephalitis patients than in controls (*p* \< 0.001 for both cytokines). The anti-inflammatory cytokine IL-10 was also higher in the anti-NMDAR patients than in controls (*p* \< 0.001) (Table [1](#T1){ref-type="table"}, Figure [1B](#F1){ref-type="fig"}). In the acute stage, a positive association was observed between YKL-40 and IL-6 levels (*r* = 0.549, *p* \< 0.001) (Figure [1D](#F1){ref-type="fig"}). ROC curves for YKL-40 were calculated using data from all 66 patients. The area under the ROC curve (AUC) was 0.9091 and the optimal cut-off value was 118.8 pg/mL (Figure [1C](#F1){ref-type="fig"}), indicate that YKL-40 has a potential diagnostic value of anti-NMDAR encephalitis.

Altered CSF levels of YKL-40 and cytokines in the follow-up for anti-NMDAR encephalitis patients
------------------------------------------------------------------------------------------------

CSF levels of YKL-40 in patients decreased significantly from 128.3 pg/mL (97--171.4 pg/mL) (onset) to 121.1 pg/mL (106.4--173 pg/mL) (3 month follow-up) (*p* = 0.015), although the latter was still higher than controls (*p* \< 0.001). CSF levels of IL-10, TNF-α and IL-6 at the 3 month follow-up were significantly lower than those at the onset of disease. (*p* \< 0.01 for all cytokines). In addition, the decrease in CSF YKL-40 levels was positively associated with the change in IL-6 levels and improvement of mRS scores (Figures [1E,F](#F1){ref-type="fig"}).

Discussion {#s4}
==========

Neuroinflammation is a common feature of anti-NMDAR encephalitis pathology; increasing evidence suggests that inflammatory cytokines and immune cells are important effectors and regulators for the inflammation and autoimmunity associated with this disease ([@B7], [@B15]--[@B18]). Autopsy studies using patient brain tissues showed that B cells interact with T cells and macrophages, inducing neuroinflammation ([@B15], [@B19]). YKL-40 levels have been reported in patients with several neuroinflammatory and neurodegenerative diseases ([@B20]). It can be expressed in macrophages/microglial cells and has been proposed as a potential marker for ongoing inflammation in a variety of human diseases ([@B21]--[@B24]). In the present study, we showed that CSF YKL-40 levels were significantly increased in patients with anti-NMDAR encephalitis and the change in YKL-40 levels at follow-up correlated positively with the improvement of mRS. Our results were similar to those reported for YKL-40 from MS and AD studies ([@B25], [@B26]). Elevated YKL-40 levels during acute attacks of anti-NMDAR encephalitis were significantly reduced after effective treatment, which was correlated with the severity of disease (mRS). Reduced levels of YKL-40 in CSF may be attributed to (i) reduced production of YKL-40 from relieved inflammation and tissue damage in the CNS after treatment; and/or (ii) reduced pro-inflammatory effect of YKL-40, which is similar to the possible associated mechanisms of YKL-40 after immunotherapy in MS ([@B27]). In our study, the 15 patients that were seen at follow-up were all treated with immunotherapy, which could have affected YKL-40 levels.

We also demonstrated that CSF levels of IL-6, a pro-inflammatory cytokine, significantly increased in anti-NMDAR encephalitis patients. IL-6 is a cytokine that is able to cause a robust, cytokine-driven expression of YKL-40 in astrocytes, which requires use of both the STAT3 and NF-κB binding elements on the YKL-40 promoter ([@B28]). Studies have shown that increased IL-6 in CSF and brain tissue could facilitate production of intrathecal anti-NMDAR autoantibody in encephalitis ([@B29], [@B30]). The role of IL-6 in the regulation of YKL-40 is also supported by *in vitro* experiments and observations in patient studies ([@B31]). In this study, we found that the changes in IL-6 correlated with changes in YKL-40, suggesting that IL-6 may contribute to YKL-40 expression and the autoantibody-induced neurological deficits observed in anti-NMDAR encephalitis.

Our study has several limitations. First, the sample size was relatively small, caution should be exercised when interpreting these results. In addition, YKL-40 is not disease specific and may be involved in other medical conditions including vascular risk factors and acute infectious diseases, all of which may affect the diagnose value of YKL-40. Finally, this was just a preliminary study, the mechanism of the increases YKL-40 in anti-NMDAR encephalitis patients remain unclear, which should be elucidated with further studies.

Conclusions {#s5}
===========

We report, for the first time, the role of YKL-40 in anti-NMDAR encephalitis. Changes in CSF YKL-40 levels positively correlated with improvement of mRS, suggesting that YKL-40 may be implicated in the pathogenesis of anti-NMDAR encephalitis. To fully understand the role YKL-40 is playing in anti-NMDAR encephalitis, additional mechanistic and experimental studies should be conducted in the future.
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